Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) from an overweight rating to an equal weight rating in a report issued on Thursday, MarketBeat.com reports ...
AbbVie, Vertex Pharmaceuticals, Eli Lilly and Company, Thermo Fisher Scientific, and Colgate-Palmolive are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool.
On Feb. 24, from west to east, you can see Mercury, Saturn, Neptune, Venus, Uranus, Jupiter and Mars, all spanning 117.5°, plus Earth under your feet—all eight known planets of our solar system!
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx, was recently ...
Vertex Pharmaceuticals’ suzetrigine gets US FDA approval for treatment of adults with moderate-to-severe acute pain: Boston Saturday, February 1, 2025, 14:00 Hrs [IST] Vertex Ph ...
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.
The FDA has approved suzetrigine, a new, non-opioid medication for adults with moderate to severe acute pain.
Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback